Therapeutic focus
20m sufferers
13 million adults in the US
7 million in key European markets
Post Traumatic Stress Disorder
PTSD is a complex and debilitating mental health condition that develops in some people who have experienced a traumatic event, for example violence, an accident, war or a natural disaster. Symptoms include intrusive memories, flashbacks, nightmares and avoidant behaviour.
PTSD is estimated to affect 13 million adults in the US, and a further 7 million in key European markets. Many sufferers don’t seek help, and the condition is underdiagnosed and underserved.
The cost of PTSD and substance use conditions
Beyond the level of individual human suffering, PTSD and substance use disorders pose a serious challenge to countries’ economic activity, public health spending and care provision. PTSD incurs an estimated cost of $232 billion in the US.
$232 billion: Estimated annual economic cost of PTSD in the US
An urgent, unmet need
There’s a key opportunity for effective treatments. But fresh hope needs a fresh approach. Solvonis offers a breakthrough solution to PTSD and further potential in other substance use conditions, through novel therapeutics that help us address the roots of these complex conditions.
With the potential to expand into other areas of mental health in time, we believe we can give hundreds of millions of patients the confidence to seek help, recover and live healthier, happier lives.